Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Mesh complications and referral
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Sepsis, organ perforation, obstruction or acute neurological harm
Mesh symptoms usually need planned specialist assessment, but fever or sepsis, pelvic abscess, peritonism, bowel obstruction, fistula, heavy bleeding, acute urinary retention with renal injury, rapidly progressive weakness or sensory loss, or severe uncontrolled postoperative pain can signal urgent organ or neurological harm.
Action: Assess observations, abdomen, urine output, residual, renal function, sepsis and relevant neurology; involve the appropriate acute gynaecology, urology or colorectal team, image or perform endoscopy according to suspected organ involvement, and contact a regional mesh centre early for complex advice.
Overview
Recognise the broad and sometimes delayed presentation of pelvic-mesh complications, document the implant accurately, investigate according to symptoms and connect patients with regional multidisciplinary specialist care.
Pelvic mesh is not one operation. A retropubic or transobturator mid-urethral sling treats stress urinary incontinence; transvaginal sheets or kits were used for prolapse; abdominal sacrocolpopexy or sacrohysteropexy suspends the apex; and colorectal mesh may support rectopexy. Material may cross vaginal, retropubic, obturator, abdominal, sacral, bladder or bowel planes. Every assessment begins by identifying what was implanted, where and when rather than using 'mesh' as a complete anatomical history.
Complications include vaginal exposure, extrusion into urinary tract or bowel, contraction, scarring, chronic infection, fistula, urinary obstruction, recurrent incontinence or prolapse, dyspareunia, partner pain and neuropathic or musculoskeletal pain. Symptoms may appear soon after surgery or years later. Some have another cause, but chronology and patient experience deserve investigation; unexplained pain must not be dismissed because mesh is not visible on a routine examination.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Referral for possible mesh complication
A patient develops new groin pain, recurrent culture-proven urinary infections and vaginal discharge several years after a mid-urethral sling. Speculum examination does not show exposed mesh. What is the most appropriate next step?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
NICE prompts clinicians to ask about new pain or sensory change in the back, abdomen, vagina, pelvis, leg, groin or perineum; vaginal discharge, bleeding, painful sex or partner pain; urinary infection, incontinence, retention, difficulty or pain voiding; bowel symptoms; and infection signs. The breadth is deliberate. Mesh can affect more than the vaginal surface, and more than one mechanism may coexist.
The consultation should be trauma-informed. Many affected patients have previously felt disbelieved, and repeated intimate examinations can be distressing. Establish the patient's own priority, explain what information is known and uncertain, offer a chaperone and the ability to stop, and avoid implying that psychological support means the symptoms are psychogenic. Pain medicine, physiotherapy and psychological care can be valuable components of multidisciplinary treatment while anatomical assessment continues.
History covers every pelvic procedure, implant type, manufacturer if known, route, date, hospital, symptom-free interval, onset, distribution and relation to movement, bladder filling, defaecation or sex. Record prior attempts at trimming or removal because the remaining anatomy changes. Review urinary and bowel function, infection cultures, bleeding, vaginal discharge, sexual function, neuropathic symptoms, mobility, sleep, work, fertility and treatment goals. Obtain operation notes and implant records rather than transferring the administrative burden to the patient.
With consent, examine abdomen, scars, posture, gait and relevant neurology. Vaginal examination assesses palpable or exposed mesh, site and approximate area, scarring, tethering, focal tenderness, discharge, bleeding and prolapse; rectal examination is added when indicated. Document findings with the person's permission and use precise language. Failure to palpate mesh is not a negative global test.
NICE recommends referral to a urogynaecologist, urologist or colorectal surgeon for suspected mesh complications, according to the original procedure and symptoms. Confirmed complications or unexplained symptoms after mesh should reach a regional specialist mesh centre. The mesh multidisciplinary team can integrate reconstructive surgeons, radiologists, pain specialists, specialist nurses, physiotherapists, psychology and colorectal expertise rather than sending the patient through disconnected single-organ clinics.
Investigation is individualised. Examination under anaesthesia may map exposure and pain when office examination is intolerable or incomplete. Cystourethroscopy assesses urinary-tract perforation; expert MRI maps position, infection or fistula for selected mesh types; expert translabial, transvaginal or transperineal ultrasound can localise some slings; CT helps assess abscess, bowel or ureteric complications; and cystography, contrast bowel studies, uroflow, residual, cystometry or neurophysiology answer specific functional questions. No single scan proves or excludes every complication.
A single vaginal mesh exposure smaller than 1 cm² can be managed initially by discussing topical oestrogen cream, using the prescribed product's regimen, with follow-up within three months. Larger exposure, extrusion, failure to resolve, a decision not to use oestrogen, or infection leads to specialist discussion of partial or complete vaginal mesh removal. Mesh perforating bladder or urethra belongs in a mesh centre with urinary reconstruction expertise; bowel involvement needs colorectal input.
Consent for removal is unusually important. Evidence about symptom relief is limited. Complete removal may be anatomically impossible or more harmful than leaving deeply incorporated material. Surgery can damage bladder, ureter, bowel, blood vessels or nerves; worsen pain; cause new urinary, bowel or sexual dysfunction; and allow stress incontinence or prolapse to recur. Partial removal can sometimes be safer and symptom-directed, while extensive removal may require staged multi-specialty surgery. The decision should match anatomy and the patient's priority, not an automatic 'all or nothing' rule.
After treatment, monitor the outcome that motivated care as well as exposure or imaging. Persistent pain after technically successful removal requires continued multidisciplinary support, not abandonment. Document and report confirmed complications through the registry and suspected device incidents through the MHRA reporting route. National restrictions and governance for new pelvic-mesh procedures must be understood separately from care of someone who already has an implant.
Key points
Ask whether the implant was a mid-urethral continence sling, transvaginal prolapse mesh, abdominal sacrocolpopexy or sacrohysteropexy mesh, or rectopexy mesh; route and site determine likely complications and expertise.
Possible symptoms include pain or altered sensation, vaginal bleeding or discharge, dyspareunia or partner pain, recurrent infection, leakage, retention or painful voiding, and bowel symptoms; onset can be delayed by years.
A normal vaginal examination does not exclude mesh contraction, deep infection, nerve or musculoskeletal pain, or mesh within bladder or bowel.
Take a complete implant and removal history and obtain operation notes, product labels, prior imaging, cystoscopy and pathology whenever possible.
NICE advises specialist referral for suspected mesh complications and regional mesh-centre referral for confirmed complications or unexplained symptoms after mesh.
Choose examination under anaesthesia, cystourethroscopy, expert MRI or ultrasound, CT, contrast studies, flow and residual, cystometry or neurophysiology only when the result answers a defined question.
For one vaginal exposure smaller than 1 cm², discuss topical vaginal oestrogen and follow up within three months; larger, extruded, persistent or treatment-declined exposure needs removal discussion.
Aetiology
01
Surface exposure or extrusion
Epithelial separation, tension, atrophy, infection or impaired healing can expose mesh vaginally or permit erosion into urinary tract or bowel.
02
Contraction and scarring
Fibrotic incorporation can shorten or tether tissue, alter organ function and produce dyspareunia or focal and referred pain.
03
Placement and organ injury
Retropubic, obturator, vaginal, abdominal or rectopexy trajectories can affect bladder, urethra, ureter, bowel, vessels, muscle or nerves.
04
Disease and treatment interaction
Recurrent prolapse or incontinence, infection, menopause, prior radiotherapy and earlier partial removal can coexist with implant-related pathology.
Pathophysiology
1
Foreign-body integration
Permanent material becomes incorporated within collagen and scar, providing support but making later dissection anatomically complex.
2
Mechanical and neural pain
Tension, folding, fixation, muscle guarding, nerve irritation and central sensitisation can sustain pain beyond a visible surface lesion.
3
Luminal contact
Mesh entering the bladder, urethra or bowel promotes persistent inflammation, infection, stone formation, bleeding, obstruction or fistula formation.
4
Support loss after removal
Removing an implant can restore mobility or remove a lesion but may also re-expose the original continence or prolapse defect.
Clinical features and red flags
Vaginal exposure
Mesh is visible or palpable through separated vaginal epithelium and may cause discharge, spotting, dyspareunia or partner pain, although a small area can be asymptomatic.
Urinary-tract extrusion
Recurrent UTI, haematuria, dysuria, pain, stones, poor flow or retention after a sling can reflect mesh within urethra or bladder and requires cystourethroscopy.
Deep pain syndrome
Pelvic, groin, leg, back, vaginal or perineal pain may reflect contraction, scarring, obturator or retropubic placement, nerve sensitisation, infection or a separate musculoskeletal cause.
Bowel or fistula complication
Defaecatory pain, bleeding, obstruction, enteric discharge, pneumaturia or faecaluria suggests bowel involvement and requires urgent colorectal or urological collaboration.
Functional recurrence
Stress leakage, urgency, voiding dysfunction or recurrent prolapse may arise from the original disease, the implant, tissue change or prior removal and must be characterised rather than presumed.
Red flags requiring action
Fever, rigors, hypotension, pelvic collection, peritonism or offensive discharge suggesting deep infection or abscess.
Acute retention, hydronephrosis, renal impairment, recurrent pyelonephritis or inability to catheterise after continence mesh.
Pneumaturia, faecaluria, faeces or urine through the vagina, bowel obstruction or concern for bladder, ureteric or bowel perforation.
Investigations
01Procedure-record reconstructionFirst step
Why
Identify every implant, route, date, site and prior partial removal before interpreting symptoms or planning surgery.
Interpretation and limitations
Operation notes, product labels and previous imaging may reveal retropubic, obturator, transvaginal, abdominal or colorectal components that require different expertise.
02Consented vaginal, rectal and neurological examination
Why
Assess exposure, extrusion, scarring, focal tenderness, prolapse, bleeding and organ or nerve signs.
Interpretation and limitations
Record site and area precisely; a normal surface examination does not exclude deep or extra-vaginal disease.
03Cystourethroscopy
Why
Inspect urethra and bladder for perforating mesh, stone, inflammation or fistula when urinary symptoms or sling position raises concern.
Interpretation and limitations
Visible intraluminal material determines urinary reconstructive referral; a normal cystoscopy does not exclude vaginal, bowel or neuropathic complications.
04Expert pelvic MRI or mesh ultrasound
Why
Map selected mesh position, collections, fistula, contraction or relationship to pain before complex treatment.
Interpretation and limitations
The modality and operator must match the implant; negative imaging cannot universally exclude clinically important mesh-related pain.
Differential diagnosis
01
Recurrent prolapse or continence disorder
Bulge, leakage, urgency and voiding symptoms may reflect recurrent pelvic-floor dysfunction with or without direct mesh involvement.
02
Genitourinary syndrome or dermatosis
Atrophy, lichen sclerosus, candidiasis and other vulvovaginal disorders can cause pain, bleeding and discharge and may coexist with exposure.
03
Urinary stone, tumour or infection
Haematuria, recurrent culture-positive infection and pain need complete standard urinary investigation even when pelvic mesh is known to be present.
04
Musculoskeletal or neuropathic pain
Hip, spine, pelvic-floor myalgia, hernia and peripheral nerve disorders can mimic or amplify mesh-pathway pain and deserve parallel assessment.
05
Pelvic malignancy or inflammatory disease
Bleeding, weight loss, mass, fistula or bowel change cannot be attributed to mesh without excluding cancer, Crohn's disease and other pathology.
Management
01First presentationBelieve, define and referFirst stepNew pain, vaginal, urinary, bowel, sexual or infection symptoms occur after any pelvic mesh procedure.+
1Screen for sepsis, retention, renal injury, obstruction, fistula, bleeding and neurological deficit and use an urgent pathway when present.
2Take a complete implant and symptom history, request operation records, and perform only consented examinations relevant to the presentation.
3Refer to urogynaecology, urology or colorectal expertise; use a regional mesh centre for confirmed complications or unexplained symptoms after mesh.
02Small exposureOffer bounded conservative careThere is a single vaginal exposure smaller than 1 cm² without extrusion, deep infection or urgent organ harm.+
1Discuss observation and topical vaginal oestrogen, checking usual contraindications and using the exact prescribed product instructions rather than inventing a class dose.
Complications
01
Infection and fistula
Chronic colonisation, abscess and abnormal communication between vagina, urinary tract and bowel can threaten sepsis and organ function.
02
Obstruction and renal harm
Sling tension, scarring or erosion can impair emptying, promote infection and rarely damage the upper tract.
03
Pain and sexual dysfunction
Dyspareunia, partner pain, pelvic or limb pain and altered sensation can substantially restrict intimacy, mobility, sleep and work.
04
Removal morbidity
Bleeding, organ, vessel or nerve injury, worsening pain and new urinary, bowel or sexual dysfunction can follow difficult dissection.
05
Recurrent support symptoms
Stress incontinence or prolapse may recur after partial or complete removal and require a new non-mesh or carefully governed treatment plan.
Monitoring and follow-up
Review a conservatively treated exposure within three months, documenting surface area, symptoms, tissue response and whether the chosen topical-oestrogen product was tolerable.
Track the patient's priority outcomes: pain distribution and function, infections, bladder emptying, bleeding or discharge, bowel function, sex, sleep, mobility and work.
After removal, monitor retention, organ injury, infection, fistula, recurrent stress incontinence or prolapse and new neurological, bowel or sexual symptoms.
Maintain regional mesh-centre ownership when symptoms persist after apparently complete treatment and coordinate pain, physiotherapy and psychological care.
Record confirmed complications in the appropriate registry and report suspected device incidents to the MHRA, while documenting that reporting does not replace treatment.
Special situations
The implant name changes the differential
An obturator sling, retropubic sling and abdominal sacrocolpopexy mesh occupy different anatomical corridors and produce different pain and organ risks.
Visibility is not causality
A small exposure may be incidental while major pain is deep, and severe mesh-related symptoms may exist without visible exposure.
Negative imaging has boundaries
Mesh conspicuity varies by material, modality and operator; an expert negative study answers only the question and anatomy it was designed to assess.
Removal is reconstructive surgery
Dissection of incorporated material may expose bladder, bowel, vessels and nerves and can reverse the continence or prolapse support it originally provided.
Support is not dismissal
Pain medicine, physiotherapy and psychological strategies can restore function alongside anatomical care and should never be framed as proof that symptoms are imagined.
Common pitfalls
01
Writing 'mesh inserted' without establishing whether it was a sling, vaginal prolapse mesh, abdominal apical mesh or rectopexy mesh.
02
Dismissing delayed symptoms, pain without visible exposure or a patient's account because one examination or scan is normal.
03
Repeatedly prescribing antibiotics for urinary symptoms without culture, residual assessment or consideration of bladder or urethral extrusion.
04
Attempting blind office trimming or local surgery without mapping the implant, prior removals, organ involvement and regional expertise.
05
Quoting topical oestrogen without the smaller-than-1-cm² selection criterion or failing to arrange review within three months.
06
Promising that complete removal is possible or will cure pain, or failing to discuss recurrent incontinence, prolapse and organ injury.
07
Treating referral, registry entry or MHRA reporting as a substitute for urgent management of sepsis, retention, fistula or obstruction.
Mesh removal may be partial, complete only as far as safely possible, staged or not appropriate; it may not relieve symptoms and can create organ injury, recurrent incontinence or prolapse and new urinary, bowel or sexual dysfunction.
Record confirmed complications in the relevant registry and report suspected device incidents to the MHRA Yellow Card system; surveillance and active treatment should proceed in parallel.
Heavy vaginal or rectal bleeding, haematuria or unexplained anaemia.
Progressive leg weakness, saddle sensory loss, severe new neurological deficit or cauda-equina features.
Severe escalating pelvic, abdominal, groin, back, perineal or leg pain with systemic deterioration.
A visible implant with tissue necrosis, extensive extrusion or rapidly worsening wound breakdown.
New symptoms after mesh in a person with previous pelvic malignancy or radiotherapy, where recurrence and injury both need evaluation.
05
CT, cystography or bowel contrast study
Why
Evaluate abscess, ureteric obstruction, organ perforation, fistula or bowel complication according to the suspected anatomy.
Interpretation and limitations
Select protocol with radiology and the mesh team; generic imaging without the clinical question can miss the relevant plane.
06Urine tests, uroflow and post-void residual
Why
Document infection, haematuria, outlet obstruction and emptying when urinary symptoms accompany mesh.
Interpretation and limitations
Culture guides antimicrobial treatment; persistent poor flow or residual supports specialist functional assessment but is not specific to mesh.
07Cystometry or neurophysiology
Why
Answer a defined continence, voiding or neurological question when it will change reconstructive or pain management.
Interpretation and limitations
These are selected tests, not screening requirements, and results are integrated with symptoms, anatomy and technical limitations.
2
Give bleeding, discharge, pain, urinary, bowel and infection safety-netting and arrange direct review within three months.
3If exposure persists, enlarges, is at least 1 cm², is extruded, the person declines oestrogen or infection is suspected, discuss specialist partial or complete vaginal removal and further imaging.
03Complex symptomsMap anatomy in a mesh centrePain is disabling or unexplained, symptoms span organs, or urinary or bowel perforation, fistula, infection or extensive mesh is possible.+
1Formulate each clinical question at a multidisciplinary meeting and select expert examination, endoscopy, MRI, ultrasound, CT, contrast or functional testing accordingly.
2Treat infection, retention, obstruction and pain while investigation proceeds, integrating specialist physiotherapy and psychological support without implying a non-organic cause.
3Agree whether conservative care, targeted partial removal, more extensive removal or staged multi-specialty reconstruction best matches the patient's priority and risk.
04Removal consentMake uncertainty explicitAny partial or complete mesh-removal procedure is considered.+
1Explain that complete removal may not be possible and neither partial nor complete removal guarantees relief of pain or other symptoms.
2Compare risks of organ, vascular and nerve injury, worsening pain, new urinary, bowel or sexual dysfunction and recurrent stress incontinence or prolapse.
3Document the intended extent, stopping boundaries, possible staging, reconstructive contingencies, expected recovery and the follow-up plan.